Lyell Immunopharma, Inc. (LYEL)

$7.31

+0.12 (+1.67%)
Rating:
Recommendation:
-
Symbol LYEL
Price $7.31
Beta 0.000
Volume Avg. 0.95M
Market Cap 1.812B
Shares () -
52 Week Range 3.57-19.84
1y Target Est -
DCF Unlevered LYEL DCF ->
DCF Levered LYEL LDCF ->
ROE -21.91% Sell
ROA -19.65% Sell
Operating Margin -
Debt / Equity 17.70% Neutral
P/E 4.57 Buy
P/B 0 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest LYEL news


Dr. Richard D. Klausner
Healthcare
Biotechnology
NASDAQ Global Select

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.